Navigation Links
Bionomics Achieves US$1 Million Milestone Payment from Genmab
Date:2/19/2008

ADELAIDE and COPENHAGEN, Feb. 19 /PRNewswire-FirstCall/ -- Bionomics Limited (ASX: BNO, US OTC: BMICY) today announced the successful completion of pre-clinical testing on the first of eight proteins licensed to US $2.6 billion Danish antibody company Genmab A/S (OMX: GEN), triggering a US $1 million milestone payment.

Under the agreement, which was executed in February 2006, Genmab acquired the exclusive worldwide rights to eight proteins identified and characterised by Bionomics using its proprietary Angene(R) angiogenesis platform. Antibodies to these proteins have potential as treatments for cancer and other diseases. At the time of the agreement, Bionomics received an upfront fee and the US $1 million is the first in a series of potential milestone payments upon achieving specified pre-clinical and clinical milestones. Bionomics will also receive milestone payments and royalties on product sales for each product reaching the market.

The US $1 million payment has been triggered with the significant progress made in the first stage of evaluation of the licensed proteins. This evaluation strongly supported the potential of a selection of the licensed proteins as antibody targets and development of a therapy to treat pathological angiogenic conditions. This milestone marks commencement of the next phase of the development program under the collaboration.

"This is a very significant milestone for Bionomics as it validates Bionomics' Angene(R) platform as a source of new treatment modalities for cancer and other conditions involving pathological formation of new blood vessels. It also reinforces for our shareholders the significant commercial potential of our collaboration with Genmab," said CEO of Bionomics Dr. Deborah Rathjen.

"We have been working in close collaboration with Genmab for several years and this latest milestone is a clear validation of the strength of this partnership which aims to bring new antibody-based treatment
'/>"/>

SOURCE Bionomics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
2. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
3. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
6. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
9. BioVascular Inc. Closes $10.87 Million Series C Financing
10. Joslin Study Identifies Key Factor That Links Metabolic Syndrome; Finding May Help Millions at High Risk of Cardiovascular Disease
11. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... VANCOUVER, British Columbia , May 30, 2015 /PRNewswire/ ... today that results from a retrospective analysis of the ... therapy in men with metastatic castrate-resistant prostate cancer (CRPC) ... effect of clusterin inhibition in men at risk for ... in the trial had at least two of five ...
(Date:5/30/2015)... CAMBRIDGE, Massachusetts y SPARTANBURG ... 30, 2015 - Nueva ... clínico terapéutico para pacientes con cáncer en los ... Research Network y Molecular Health proporcionarán a los ...   La Guardian Research Network y ...
(Date:5/30/2015)... , May 30, 2015  Eisai Inc. announced today the ... that eribulin met the study,s primary endpoint evaluating overall survival ... (ADI), two types of advanced soft tissue sarcoma. These data ... of the American Society of Clinical Oncology (ASCO) in ... conference on Saturday, May 30, and also in an oral ...
Breaking Medicine Technology:OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 2OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 3OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 4OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 5OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis 6Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 2Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 3Nueva colaboración para ampliar el acceso al ensayo clínico terapéutico para pacientes con cáncer en EEUU 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 2Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 3Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 4Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 5Phase 3 Trial Investigating Eribulin in Patients with Advanced Soft Tissue Sarcoma Demonstrated Improved Overall Survival 6
... 2011 ConvaTec Healthcare, a world-leading developer, manufacturer and ... care, today announced that, following a review of current ... refinancing of its senior secured term loans originally entered ... ConvaTecConvaTec is a leading developer and marketer of innovative ...
... March 17, 2011 Giant Eagle®, the region,s leading ... Association,s (ADA) prestigious Chairman,s Citation Award. Giant ... which recognizes the outstanding accomplishments of individuals, corporations, institutions ... and have had a positive impact in advancing the ...
Cached Medicine Technology:ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 2ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 3Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 2Giant Eagle® Receives American Diabetes Association Chairman's Citation Award 3
(Date:5/30/2015)... York, New York (PRWEB) May 30, 2015 ... to pay $100 million in punitive and compensatory ... ) plaintiff who suffered serious complications following implantation ... According to a verdict rendered on May 28th ... $25 million in compensatory damages after the jury ...
(Date:5/30/2015)... Belton, Texas (PRWEB) May 30, 2015 ... Client Services Web Portal that gives hospices the ability ... the industry. Because of this business model, EHO has ... offer better pricing to its clients and survive among ... interface with hospice management systems three years ago, it ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 Nicole ... the Disability Income Associate (DIA) designation to further ... DIA designation is designed for insurance advisors, health ... further their knowledge and expertise associated with the ... the DIA designation is only the latest accomplishment ...
(Date:5/30/2015)... 30, 2015 The Brain Fitness Education ... with ONEgeneration Senior Enrichment Center, headed by 1Heart Client ... Guzman and Brain Fitness Program Director Tee Barr. , ... learned that there are many ways to enrich and ... the residents the different ways to overcome dementia and ...
(Date:5/30/2015)... Wixom, Michigan: Proof. Pest Control, a family-owned company ... new twist to its robust line of services-a 100% ... for general pest management. , “We like killing ... Branch Manager. “The average person cringes when they see a ... problems that most people don’t even want to think about. ...
Breaking Medicine News(10 mins):Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 2Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 3Health News:Boston Scientific Transvaginal Mesh Lawsuit Trial Ends With $100 Million Verdict 4Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 2Health News:1Heart Caregiver Services Brings Brain Fitness Education Seminar at ONEgeneration 3Health News:Proof. Pest Control-Now Offering 100% Organic Pest Control in Southeast Michigan 2
... ... an employee responds falsely to a confirmation request. While paper confirmations make it difficult ... boards supporting the use of secure electronic confirmations now give companies a better way to ... ...
... Radical ... ... Skinny on Willpower! The publishing industry is in the midst of a revolutionary change, and nowhere ... On series. The series, recent hit, The Skinny On Willpower , addresses one of ...
... ... and advice from a qualified medical professional. Award-winning Board Certified New York City Plastic Surgeon, Dr. ... ... people, losing weight to achieve the ultimate healthy and fit body is a constant goal and ...
... ... R. Macdonald announced the launch of a new plastic surgery blog dedicated to real ... chronicle their cosmetic surgery experience through detailed daily accounts of their progress, and provide ... ...
... to change your drinking habits, researcher says , THURSDAY, May ... because of a reported link with a type of kidney cancer, ... , "The data in this study provide no concrete evidence of ... lead author, Nicholas Timpson, a lecturer in genetic epidemiology at the ...
... help urologic surgeons spare the neurovascular bundle (NVB) (which ... robotic assisted laparoscopic prostatectomy (RALP) for the treatment of ... at the ARRS 2010 Annual Meeting in San Diego, ... treatment of prostate cancer. "However it is limited by ...
Cached Medicine News:Health News:Brian Fox to Speak on Audit Confirmation Fraud at the 2010 IAPP Annual Forum and Expo 2Health News:Readers and Reviewers Rave about 'The Skinny On Willpower' 2Health News:Readers and Reviewers Rave about 'The Skinny On Willpower' 3Health News:Readers and Reviewers Rave about 'The Skinny On Willpower' 4Health News:Dr. Keith Berman's Beach Body Secrets: 7 Simple Tips for Weight Loss Success 2Health News:Dr. Keith Berman's Beach Body Secrets: 7 Simple Tips for Weight Loss Success 3Health News:San Francisco Plastic Surgeon Releases Plastic Surgery Patient Recovery Blog 2Health News:Study Disputes Link Between Milk and Kidney Cancer 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: